337 related articles for article (PubMed ID: 34617186)
21. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib.
Tachibana T; Tanaka M; Noguchi Y; Najima Y; Sadato D; Harada Y; Tamai Y; Doki N; Nakajima H
Hematology; 2024 Dec; 29(1):2360843. PubMed ID: 38828928
[TBL] [Abstract][Full Text] [Related]
23. Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and
Kayser S; Sartor C; Luskin MR; Webster J; Giglio F; Panitz N; Brunner AM; Fante M; Lutz C; Wolff D; Ho AD; Levis MJ; Schlenk RF; Papayannidis C
Haematologica; 2022 Sep; 107(9):2064-2071. PubMed ID: 35142153
[TBL] [Abstract][Full Text] [Related]
24. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
Aldoss I; Afkhami M; Yang D; Gu Z; Mokhtari S; Shahani S; Pourhassan H; Agrawal V; Koller P; Arslan S; Tomasian V; Al Malki MM; Artz A; Salhotra A; Ali H; Aribi A; Sandhu KS; Ball B; Otoukesh S; Amanam I; Becker PS; Stewart FM; Curtin P; Smith E; Telatar M; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pullarkat V
Am J Hematol; 2023 Jun; 98(6):848-856. PubMed ID: 36880203
[TBL] [Abstract][Full Text] [Related]
25. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.
Badar T; Szabo A; Wadleigh M; Liedtke M; Arslan S; Siebenaller C; Aldoss I; Schultz E; Hefazi M; Litzow MR; Kuo E; Wang A; Curran E; Shallis RM; Podoltsev N; Balasubramanian S; Yang J; Mattison R; Burkart M; Dinner S; Advani A; Atallah E
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):556-560.e2. PubMed ID: 32291234
[TBL] [Abstract][Full Text] [Related]
26. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
[TBL] [Abstract][Full Text] [Related]
28. [Antibody therapy for acute lymphoblastic leukemia].
Hatta Y
Rinsho Ketsueki; 2020; 61(8):922-928. PubMed ID: 32908056
[TBL] [Abstract][Full Text] [Related]
29. Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Stein AS; Kantarjian H; Gökbuget N; Bargou R; Litzow MR; Rambaldi A; Ribera JM; Zhang A; Zimmerman Z; Zugmaier G; Topp MS
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1498-1504. PubMed ID: 31002989
[TBL] [Abstract][Full Text] [Related]
30. [Allogeneic hematopoietic stem cell transplantations for relapsed and refractory acute lymphoblastic leukemia following inotuzumab ozogamicin treatment].
Morishige S; Yamasaki Y; Oya S; Nakamura T; Yamaguchi M; Aoyama K; Mouri F; Mizushima Y; Nakashima O; Nagafuji K
Rinsho Ketsueki; 2022; 63(4):271-276. PubMed ID: 35491216
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Jabbour E; Sasaki K; Short NJ; Ravandi F; Huang X; Khoury JD; Kanagal-Shamanna R; Jorgensen J; Khouri IF; Kebriaei P; Jain N; Alvarado Y; Kadia TM; Paul S; Garcia-Manero G; Dabaja BS; Burger JA; DiNardo CD; Daver NA; Montalban-Bravo G; Yilmaz M; Ohanian M; Ferrajoli A; Jacob J; Rostykus M; Garris R; O'Brien S; Kantarjian HM
Cancer; 2021 Jun; 127(12):2025-2038. PubMed ID: 33740268
[TBL] [Abstract][Full Text] [Related]
32. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
[TBL] [Abstract][Full Text] [Related]
33. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
[TBL] [Abstract][Full Text] [Related]
34. Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases.
Okura M; Ida N; Yamauchi T
Intern Med; 2020 Aug; 59(16):2047-2051. PubMed ID: 32389945
[TBL] [Abstract][Full Text] [Related]
35. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.
Fujishima N; Uchida T; Onishi Y; Jung CW; Goh YT; Ando K; Wang MC; Ono C; Matsumizu M; Paccagnella ML; Sleight B; Vandendries E; Fujii Y; Hino M
Int J Hematol; 2019 Dec; 110(6):709-722. PubMed ID: 31655984
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic Hematopoietic Stem Cell Transplantation for Adult Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Second Complete Remission.
Kaito S; Kurosawa S; Najima Y; Sakaida E; Shingai N; Fukuda T; Tachibana T; Uchida N; Ozawa Y; Sawa M; Nakazawa H; Ota S; Kato J; Nakamae H; Katayama Y; Eto T; Tanaka J; Kanda Y; Atsuta Y; Arai Y; Kako S;
Transplant Cell Ther; 2022 Jun; 28(6):326.e1-326.e10. PubMed ID: 35306218
[TBL] [Abstract][Full Text] [Related]
37. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
Jabbour EJ; Gökbuget N; Kantarjian HM; Thomas X; Larson RA; Yoon SS; Ghobadi A; Topp MS; Tran Q; Franklin JL; Forman SJ; Stein AS
Cancer; 2019 Dec; 125(23):4181-4192. PubMed ID: 31433496
[TBL] [Abstract][Full Text] [Related]
38. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia.
Aldoss I; Song J; Stiller T; Nguyen T; Palmer J; O'Donnell M; Stein AS; Marcucci G; Forman S; Pullarkat V
Am J Hematol; 2017 Sep; 92(9):858-865. PubMed ID: 28494518
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab.
Wudhikarn K; King AC; Geyer MB; Roshal M; Bernal Y; Gyurkocza B; Perales MA; Park JH
Blood Adv; 2022 Mar; 6(5):1432-1443. PubMed ID: 35042232
[TBL] [Abstract][Full Text] [Related]
40. [Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].
An LL; Zhao DF; Hou RF; Guan HH; Yan H; Lin YH; Tong CR; Wu T; Liu SY
Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):911-916. PubMed ID: 38185520
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]